THALIA THERAPEUTICS PLC

• ⚠

  Insolvency history on file

  Companies House holds prior insolvency events for this company. Detail and outcome on the official register.

• ◆

  Material uncertainty over going concern

  As stated in the respective disclosures, these conditions along with the other matters set out in those disclosures, indicate that a material uncertainty exists that may cast significant doubt on the Group's and the Company's ability to continue as a going concern.

• ·

  Going-concern uncertainty disclosed

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. THALIA THERAPEUTICS PLC 2026-03-17 → present
2. N4 PHARMA PLC 2017-05-02 → 2026-03-17
3. ONZIMA VENTURES PLC 2015-10-14 → 2017-05-02
4. ULTIMA NETWORKS PLC 1998-04-14 → 2015-10-14
5. MICROVITEC PUBLIC LIMITED COMPANY 1979-07-06 → 1998-04-14

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Gravita Audit II Limited

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“As stated in the respective disclosures, these conditions along with the other matters set out in those disclosures, indicate that a material uncertainty exists that may cast significant doubt on the Group's and the Company's ability to continue as a going concern.”

Group structure

1. THALIA THERAPEUTICS PLC · parent
   1. N4 Pharma UK Limited 100% · United Kingdom · Delivery of vaccines and therapeutics
   2. Nanogenics Limited 71.21% · United Kingdom · Research and experimental development on biotechnology

Significant events

• “Nigel Theobald resigned on 24 February 2026 with his share options remaining in place.”
• “Dr David H Solomon was appointed Chief Executive Officer on 24 February 2026.”
• “The Company changed its name from N4 Pharma Plc to Thalia Therapeutics Plc on 18 March 2026.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

11

last 12 months

Capital events

3

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.